Endocrine Abstracts

Objectives: The majority of patients with differentiated thyroid carcinoma (TC) have an excellent prognosis, with a 5-year survival rate of 98.3%, and only rarely reaches an advanced stage of disease. The present study aims to identify the clinicopathological and epidemiological features at the time of diagnosis of a group of patients who required to be treated with systemic therapy with tyrosine-kinase inhibitors (TKI).Methods: We retrospectively evalua...

Introduction: The majority of patients with radioiodine-refractory thyroid carcinoma (RAIR-TC) have an indolent disease and require active surveillance (AS) only, while those with progression of the disease (PD) may benefit from local treatment (LT) or systemic therapy with tyrosine-kinase inhibitors (TKI). In the literature, no data about the real impact of LTs in avoiding/delaying systemic treatment in RAIR-TC patients are present.Objective: This study...

Lenvatinib is a tyrosine kinase inhibitor (TKI), approved for the management of locally recurrent or metastatic, progressive, radioactive iodine–refractory differentiated thyroid cancer (DTC). A side effect of this drug is the tracheoesophageal fistula, described in 14.7% of patients. When this side effect is present, the interruption/withdrawn of the TKI is required and in this case no valid therapeutic options are described. We present the case of a 63-year-old woman pa...